Uterine sarcoma Cancer
Conditions
Interventions
All participants will be asked questions about their demographics, medical and family history, and any symptoms. Additional information will be taken from their medical records, including information
Sponsors
University of Leicester
Eligibility
Sex/Gender
Female
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Uterine sarcoma 2. Aged 18 years or older 3. Female
Exclusion criteria
Exclusion criteria: 1. Male 2. Under 18 years 3. Not previously undergone treatment for a uterine sarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Body Mass Index (BMI) is measured using height and weight recorded with a stadiometer and calibrated scale at baseline (visit 1) 2. Uterine sarcoma diagnostic and treatment data are measured using clinical records review at baseline (visit 1) 3. Medical and family history is measured using patient interview and clinical records review at baseline (visit 1) 4. Symptom burden is measured using a symptom checklist questionnaire at baseline (visit 1) and approximately every 3 months 5. Circulating tumor DNA (ctDNA) presence is measured using a personalized, tumor-informed ctDNA assay (e.g. Signatera) from blood samples at baseline (visit 1) and approximately every 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient experience of diagnosis, treatment, follow-up, and views on prognostic blood testing is measured using a semi-structured qualitative interview at any time following recruitment | — |
Countries
England, United Kingdom
Contacts
Public ContactEsther Moss
Outcome results
None listed